To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
Within the Institute, the "Funding Research and Technology Transfer" team is at your disposal to identify the scientists and the skills you need to set up a joint project, to define the terms of a collaboration contract or study.
Whether you are an academic, a SME or an industrialist, our team informs and advices you about the possibilities of consortium assembly, technology transfer, patent licensing or use of our platforms.
The team is also at the disposal of the researchers of the institute to accompany them in achieving their valorization objectives.
All the news of the Institute of life sciences Frédéric Joliot
Helicenes are synthetic molecules with attractive properties for physicists expert in materials but also for biologists. A collaboration led by chemists from the SCBM (CEA-Joliot) and involving the NIMBE (CEA-Iramis) allowed the synthesis of a particular class of helicenes.
A partnership between the François Jacob Institute of Biology/CEA, The Frédéric Joliot Institute for Life Sciences/CEA and CellTechs (a Sup'Biotech lab) has led to a new approach for modeling Alzheimer's disease in vitro.
Researchers from the SCBM and the IRAMIS (CEA/CNRS) have develop a 14C labeling method for therapeutic molecules based on dynamic Misspelled Wordcarbone dioxide exchange. This one step method generates far less radioactive waste. By facilitating some preclinical and clinical steps, it should eventually help to speed up the marketing applications of some new drug discoveries.
A collaboration involving the Sainte-Anne Hospital, the SHFJ, the Saint-Antoine research center and the ICM identified, through a PET brain imaging study in patients with Alzheimer's disease, two distinct kinetic profiles of the cerebral neuroimmune response, that impact the disease progression differently. Researchers propose an original model of neuroinflammation, likely to open new therapeutic avenues.
Thanks to complementary imaging techniques, researchers from the SHFJ and NeuroSpin have shown that the physical blood-brain barrier (BBB) disruption is not necessarly enough to deliver some drugs into the brain, especially when there are recognized and supported by efflux transporters.
An international collaboration of researchers in psychiatry, led by a team from NeuroSpin, has shown that machine learning algorithms identify a neuroanatomical signature of schizophrenia that is reproducible in the various image acquisition centers and for the different stages of the disease evolution. These results offer prospects for the early detection and management of people at risk of psychotic transition.
A collaboration involving the SB2SM (I2BC@Saclay) works on bio-inspired processes to recycle carbon dioxide (CO2), a major environmental problem. Researchers have formulated a new catalyzer very efficient for reducing CO2 in water. The study has been published in Chemical Communications.
As part of the InFoR-Autism scientific program involving NeuroSpin, a new neuroimaging study has revealed a correlation between decreased local anatomical connectivity and social cognitive deficits in people with autism spectrum disorders (ASD). Published in the renowned journal Brain, the results challenge the dominant theoretical model explaining ASD and could pave the way for the exploration of new therapeutic approaches.
The goal of the PRIME-DE data exchange is to make primate brain imaging datasets acquired in laboratories available to the entire scientific community. PRIME-DE was created by an international consortium of 22 teams including one from NeuroSpin, all working with macaques. The PRIME-DE initiative, presented in an article published in Neuron should enhance the statistical relevance of acquired data and limit the number of animals used in research.
Rad52 has garnered great attention lately as a promising target in the battle against certain types of breast cancer. A team from IRCM, in partnership with researchers from the Frédéric-Joliot and Gustave Roussy Institutes, has shed new light on this protein.
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.